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Edited by Michael R. BubbAbstract Malignant mesothelioma (MM) is a fatal type of can-
cer. We studied the role of the redox-active protein thioredoxin-1
(Trx-1) in apoptosis induced in MM cells and their non-malig-
nant counterparts (Met-5A) by a-tocopheryl succinate (a-
TOS) and TNF-related apoptosis-inducing ligand (TRAIL).
MM cells were susceptible to a-TOS and less to TRAIL, while
Met-5A cells were susceptible to TRAIL and resistant to a-
TOS. MM cells expressed very low level of the Trx-1 protein,
which was high in Met-5A cells, while the level of Trx-1 mRNA
was similar in all cell lines. Downregulation of Trx-1 further sen-
sitised Met-5A cells to TRAIL but not to a-TOS. Our data sug-
gest that the role of Trx-1 in apoptosis modulation is unrelated to
its anti-oxidant properties.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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ligand1. Introduction
Malignant mesothelioma (MM) is a fatal neoplastic disease
with poor prognosis and no reliable cure at present, which
makes it a considerable challenge despite its relatively rare
occurrence [1,2]. Etiology of MM is tightly linked to occupa-
tional hazard, in particular breathing asbestos ﬁbres [3].
Although asbestos mining and processing is now banned in
developed countries, the number of MM cases will increase
due to its very long latency, and the frequency of new cases
is not predicted to plateau before 2015 [4].
The reasons for low response of MM to treatment are not
exactly known but may include a relatively high correlation
of MM patients with SV40 positivity, although this premise
is non-conclusive at present [5]. Another reason for resistance
of MM to chemotherapy, often relying on induction of apop-
tosis in the target cancer cells, is a relatively poor response of
MM cells to inducers of programmed cell death [6,7], which
may be associated with SV40-dependent inactivation of p53
[8] or activation of the potent pro-survival mediator Akt [9].Abbreviations: ELISA, enzyme-linked immuno-sorbent assay; FCS,
fetal calf serum; MM, malignant mesothelioma; Q-PCR, quantitative
reversed-transcription PCR; ROS, reactive oxygen species; siRNA,
short interfering RNA; a-TOS, a-tocopheryl succinate; TRAIL, TNF-
related apoptosis-inducing ligand; Trx-1, thioredoxin-1
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doi:10.1016/j.febslet.2006.04.019Further, enhanced expression of the anti-apoptotic bcl-2 fam-
ily proteins may also contribute to resistance of MM cells to
apoptosis [10]. Novel approaches that would overcome resis-
tance of MM cells to apoptosis and would be applicable to
treatment of MM patients are therefore required.
We have been studying the role of vitamin E analogues, epit-
omised by the redox silent a-tocopheryl succinate (a-TOS), as
pro-apoptotic and anti-cancer agents [11] and have shown that
they induce apoptosis selectively in malignant cells while being
largely non-toxic to normal cells and tissues [12–15]. Impor-
tantly, too, we have shown that a-TOS suppresses human
MM in two diﬀerent mouse models [16,17]. The mechanism
underlying apoptosis induced by a-TOS includes induction
of the intrinsic apoptotic pathways [18–20], which also contrib-
ute to sensitisation of MM cells to the selective immunological
apoptogen TNF-related apoptosis-inducing ligand (TRAIL)
[14,21], similarly as shown for other pharmacological inducers
of apoptosis in MM cells [22]. The selective apoptogenic eﬀect
of a-TOS towards MM cells can be ascribed to high levels of
reactive oxygen species (ROS) generated in the cells as a re-
sponse to the vitamin E analogue, which was not observed in
non-malignant mesothelial cells [17]. This paradigm was
shown for apoptosis induction by a-TOS in other cells
[15,18,23,24]. In fact, generation of ROS appears to be obliga-
tory for malignant cells to undergo apoptosis when challenged
with a-TOS, since their eﬃcient scavenging by antioxidant pro-
teins, such as superoxide dismutase (SOD), as well as by both
small anti-oxidants has proven anti-apoptotic [17,25].
Of anti-oxidant enzymes, thioredoxin-1 (Trx-1) has been
suggested to play a diverse role in cancer cells. Not only does
it act as a redox-active protein with anti-oxidant activity [26]
and redox modulatory eﬀector of mediators of signalling path-
ways [27], but it also regulates pathways, such as MAP kinase
signalling, in a redox-independent manner [28]. In this commu-
nication, we studied the role of Trx-1 in apoptosis induction of
MM cells and their non-malignant counterparts exposed to a-
TOS whose induction of apoptosis requires ROS, and to
TRAIL that induces apoptosis via a redox-independent mech-
anism [25]. We show here that, surprisingly, Trx-1 appears
more important for TRAIL- than for a-TOS-induced pro-
grammed cell death in MM cells.2. Materials and methods
2.1. Cell culture and treatment
The MM-BI (biphasic), Meso-2 (sarcomatose) and Ist-Mes-2 (epi-
thelioid) human MM cell lines were used [29]. The mesothelial cell
line, Met-5A (ATTC, Rockville, MD, USA), was used as a non-blished by Elsevier B.V. All rights reserved.
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with 100 units/ml penicillin, 100 lg/ml streptomycin, and 10% fetal
calf serum. Cells were treated with human recombinant TRAIL pre-
pared as described elsewhere [30] and a-TOS (Sigma, Castle Hill,
NSW, Australia) at 30 ng/ml and 50 lM, respectively. a-TOS was
dissolved in ethanol and diluted in complete DMEM to the ﬁnal
concentration, and was added to cells at 0.1% (v/v) of ethanol. Cells
deﬁcient in mtDNA (q0 phenotype) were prepared and cultured as
described elsewhere [18].2.2. Apoptosis detection
Apoptosis was quantiﬁed using the annexin V-FITC method, which
detects phosphatidyl serine (PS) externalised in early phases of apopto-
sis [31]. Brieﬂy, cells were treated with a-TOS or TRAIL. Floating and
attached cells were collected, washed and re-suspended in the binding
buﬀer containing 2 ll annexin V-FITC (both BD Pharmingen, North
Ryde, NSW, Australia), incubated for 30 min at 4 C in the dark, sup-
plemented with propidium iodide (PI), and analysed by ﬂow cytometry
(FACScalibur, BD Pharmingen).2.3. Western blotting
Cells were treated as indicated, lysed in whole cell lysis buﬀer,
spun down, the supernatants mixed with the sample buﬀer, the pro-
tein denatured and electrophoresed in 12% polyacrylamide gels. Sep-
arated proteins were transferred to a nylon membrane and blocked
with 5% skim milk in TBS buﬀer for 30 min at room temperature.
Immuno-detection was performed overnight at 4 C in TBS buﬀer
using anti-Trx-1 IgG (Fl-105) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or anti-MnSOD IgG (Calbiochem), and with
anti-actin IgG (I-19) (Santa Cruz) as a loading control. After incu-
bation with HRP-conjugated secondary IgG (Santa Cruz), the blots
were developed using the Supersignal Chemiluminescence Kit (Pierce
Biotechnology, Rockford, IL, USA), and the membranes were
scanned using the Universal Hood II and Quantity One software
(both BioRad, Hercules, CA, USA).2.4. Downregulation of Trx-1 using short-interfering RNA (siRNA)
Two Trx-1 siRNA sequences (Proligo Primers and Probes, Lis-
more, NSW, Australia) were used. Duplex 1: sense 5 0-GUC UUC
AAC GGG UUC ACC GdTdT-3 0, antisense 5 0-CGG UGA ACC
CGU UGA AGA CdTdT-3 0, corresponding to the target sequence
5 0-AAC CAG TTG CCA TCT GCG TGA-3 0; duplex 2: sense 5 0-
CUG UCA GGA UGU UGC UUC AdTdT-30, antisense 5 0-UGA
AGC AAC AUC CUG ACA GdTdT-30, corresponding to the tar-
get sequence of 5 0-GAC TGT CAG GAT GTT GCT TCA-30. Non-
silencing (NS) siRNA (Qiagen, Doncaster, Vic., Australia) used was:
sense 5 0-UUC UCC GAA CGU GUC ACG UdTdT-30, antisense
5 0-UUC UCC GAA CGU GUC ACG UdTdT-3 0. For treatment,
cells were seeded in 6-well plates at a 7 · 104 and left overnight to
recuperate. A solution was made up of 5 lg siRNA duplexes dis-
solved in 100 ll of cell culture medium plus 15 ll of OligofectAmine
(Invitrogen, Mt. Waverley, Vic., Australia). The solution was incu-
bated for 30 min at room temperature and added to each well con-
taining 1.9 ml of cell medium. The cells were incubated for 6 h, after
which the medium was removed and complete DMEM added. The
cells were incubated for 48 h and then assessed by ELISA for Trx-1
protein level and used in experiments.2.5. Trx-1 ELISA
The enzyme-linked immuno-sorbent assay (ELISA) for Trx-1 was
based on the use of the monoclonal ‘capture’ IgG 1B3 and the bio-
tinylated monoclonal ‘light up’ IgG 2B1 [32]. Brieﬂy, the unlabelled
IgG 1B3 was diluted to the ﬁnal concentration of 20 lg/ml and added
to 96-well plates at 100 ll/well and allowed to attach. To determine
the concentration of Trx-1 in samples, plates were incubated at
4 C overnight with individual samples, and this was followed by
the antigen capture steps: 100 ll of the biotinylated IgG 2B1 (diluted
1:500) was added to each well, the plates were incubated at 37 C for
2 h, reacted with 100 ll of avidin–horseradish–peroxidase conjugate
(BioRad) diluted 1:1000, and the colour was developed using
3,3 0,5,5 0-tetramethylbenzidine. Absorbance was read in a plate reader
set at 620 nm.2.6. Thioredoxin reductase assay
The method is based on thioredoxin reductase (TrxR)-mediated
reduction of SH groups in the substrate, Trx, which is detected using
DTNB, as described in detail in a previously published protocol [33].
The activity was expressed as nmol/min/mg protein of NADPH
formed.2.7. Quantitative real-time-polymerase chain reaction (Q-PCR)
Q-PCR was used to assess levels of Trx-1 mRNA in MM and Met-
5A cells, essentially as reported elsewhere [17]. The primers used for
Trx-1 were forward: 5 0-CCT TTC TTT CAT TCC CTC TCT TGA
A-3 0, reverse: 5 0-GCA ACA TCC TGA CAG TCA TCC A-3 0; for
18S-M primer: 5 0-TTC GAG GCC CTG TAA TTG GA-3 0, reverse:
5 0-GCA GCA ACT TTA ATA TAC GCT ATT GG-3 0. Total mRNA
was extracted with Trizol (Sigma) and puriﬁed using RNeasy Mini
Columns (Qiagen). cDNA was synthesised and the product quantiﬁed
on the TaqMan real-time PCR instrument using the SYBRGreen mas-
ter mix (Invitrogen). The results were then analysed using the com-
puter software supplied with the PCR program. Before Q-PCR, the
reaction was veriﬁed by standard RT-PCR followed by EtBr visualisa-
tion of the products on a 2% agarose gel.2.8. Statistical analysis
All experiments were conducted at least three times, and data are
shown as means ± S.E. Where shown, statistical signiﬁcance
(P < 0.05) was evaluated using the Student’s t-test.3. Results and discussion
In this study we were interested in the potential role of Trx-
1, an antioxidant protein that regulates apoptosis in redox-
dependent and -independent manners, in programmed cell
death induced in MM cells by two diﬀerent agents. One of
them is a-TOS that causes generation of ROS as an early event
in apoptosis induction, the other is TRAIL acting in an ROS-
independent way [18,23]. For these studies, we used three MM
cell lines of diﬀerent phenotypic origin, i.e. the epithelioid Ist-
Mes-2, the sarcomatose Meso-2 and the mixed (biphasic) phe-
notype MM-B1 cell lines, and a non-malignant mesothelial cell
line Met-5A.
We ﬁrst explored apoptosis induced by a-TOS and TRAIL.
Fig. 1 shows a converse eﬀect of the two inducers on apoptosis
in the malignant and non-malignant cells. While Met-5A cells
were more resistant to a-TOS than their malignant counter-
parts, TRAIL was surprisingly more apoptogenic for the
non-malignant cells.
a-TOS is known to induce apoptosis by triggering the intrin-
sic pathway(s) involving generation of ROS. We have shown
that small as well as proteineous antioxidants, including
MnSOD, suppress apoptosis induced by the vitamin E ana-
logue, concomitant with lowering of ROS accumulation
[15,18,24]. We thus studied here the role of the mitochondrial
function and also of MnSOD expression. To do so, we pre-
pared mtDNA-deﬁcient (q0) cells by long-term incubation with
sub-lethal doses of EtBr [18]. Our recent data show that q0 cells
are more resistant to a-TOS compared to their parental coun-
terparts [18,25]. This does not seem to be the case for MM-BI
q0 cells, since they showed a similar level of apoptosis as did
the parental MM-BI cells, and a similar pattern was also ob-
served when the cells were exposed to TRAIL (Fig. 2A). We
next inspected the level of expression of the MnSOD protein
by Western blotting both in the individual cell lines as well
as in the MM-BI q0 cells. Fig. 2B reveals that MnSOD is ex-
pressed at comparable levels in the non-malignant Met-5A
Fig. 2. Deﬁciency in mtDNA does not protect MM cells from a-TOS-
induced apoptosis. (A) Parental MM-BI and MMB-I-q0 cells were
seeded in 24-well plates, allowed to reach 60–70% conﬂuency, and
exposed to a-TOS and TRAIL at concentrations and for periods
indicated. The cells were then harvested and assessed for the level of
apoptosis using the annexin V method. (B) Western blotting for
expression of MnSOD (1-MM-BI, 2-MM-BI-q0) and (C) ﬂow
cytometric evaluation (MFI, mean ﬂuorescence intensity) for expres-
sion of Trx-1 in MM-BI (Par, parental cells) and MM-BI-q0 cells. Data
shown in (A) and (C) are mean values ± S.D. (n = 3), images in (B) are
representative of three independent experiments.
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Fig. 1. Apoptosis induction in non-malignant mesothelial and MM
cells by a-TOS and TRAIL. Met-5A, MM-BI, Meso-2 and Ist-Mes-2
cells were seeded in 24-well plates and allowed to reach 60–70%
conﬂuency. The cells were exposed to 50 lM a-TOS (upper panel) and
30 ng/ml hrTRAIL (lower panel) for the periods indicated. The cells
were then harvested and assessed for the level of apoptosis using the
annexin V method. Data shown are mean values ± S.D. (n = 5). The
asterisk indicates statistical diﬀerence (P < 0.05) in apoptosis in Met5A
cells and the malignant cell lines.
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expression was found for the Meso-2 q0 cells.
Since ROS have been strongly implicated in apoptosis induc-
tion by a-TOS, we assessed the cytosolic levels of Trx-1 in MM
cells and the non-malignant Met-5A cells. Fig. 3 demonstrates
a surprising paradigm, revealing similar level of Trx-1 expres-
sion on the level of mRNA (detected by both the conventional
RT-PCR and by Q-PCR), while very high levels of the Trx-1
protein were found in Met-5A cells with all three malignant
cell lines showing levels of Trx-1 close to the detection limit.
This unexpected diﬀerence in Trx-1 protein expression between
Met-5A cells and the MM cell lines was observed both using
Western blotting and by the very sensitive ELISA assay. More-
over, this was conﬁrmed by immunoﬂuorescence microscopy
of MM and Met-5A cells (not shown). This cannot be ex-
plained by secretion of Trx-1 by MM cells, since we found
barely detectable levels of Trx-1 protein in both MM and
Met5A cell-conditioned medium (not shown). This is a surpris-
ing ﬁnding and suggests that mRNA expression of Trx-1 does
not necessarily correspond to the extent of the protein expres-
sion. Although, to the best of our knowledge, this paradigm
has not been shown for Trx-1 before, it is known that not al-
ways high levels of mRNA expression reﬂect expression of the
corresponding protein, as shown, for example, for 15-lipoxyge-
nase, whose mRNA is high in hematopoietic precursors but is
not translated before the cells mature into erythrocytes [34].
Notwithstanding, our data clearly show that the Trx-1 protein
is highly expressed in the non-malignant Met-5A cells and is
extremely low in all three MM cell lines, while levels of the
MnSOD protein are comparable in all tested lines. Moreover,
thioredoxin reductase, important for maintaining Trx-1 in its
functional form, showed comparable activity in MM and
Met5A cells (not shown). Since these cell lines represent meso-
thelioma cells of diﬀerent phenotypic origin, it is likely that our
results may be extrapolated to other MM cell lines as well. It is
beyond the scope of this manuscript to investigate the reasons
for the discrepancy in Trx-1 mRNA and protein expression in
MM and Met-5A cells, but, in analogy to 15-lipoxygenase, it is
possible that the Trx-1 mRNA is not translated eﬃciently in
the de-diﬀerentiated MM cell lines.
Because the non-malignant Met-5A and MM cells feature
diﬀerent expression of Trx-1 and since they are also diﬀerently
susceptible to apoptosis initiation by a-TOS and TRAIL, we
next studied the eﬀect of modulation of the Trx-1 level on
apoptosis upon exposure to the two inducers. We thus at-
tempted to overexpress Trx-1 in MM cells. However, we did
not succeed in increasing the levels of the Trx-1 protein in
the transfectants, probably due to its strict regulation by the
MM cells. It is possible that some cell types have a mechanism
whereby controlling very tightly the cytosolic levels of Trx-1
protein or degrading the newly synthesised protein very eﬃ-
ciently. Notwithstanding, this interpretation is highly specula-
tive at this stage and needs further investigations, which are
beyond the cope of this manuscript. Not surprisingly thus,
both the parental cells and the ‘transfectants’ responded to
both apoptogens in a similar way (not shown). Conversely,
we studied the eﬀect of knocking down Trx-1. To do this,
two diﬀerent duplexes of Trx-1 siRNA were used to knock
down Trx-1 protein in Met-5A and MM-BI cells. Of them,
duplex 1 suppressed Trx-1 protein expression by 80% and
duplex to by 60% in MM-BI cells, while in Met-5A cells,
duplex 1 was ineﬃcient and duplex 2 knocked down Trx-1
Fig. 3. Trx-1 levels are dramatically diﬀerent in the non-malignant mesothelial and MM cells. Met-5A, MM-BI, Meso-2 and Ist-Mes-2 cells were
assessed for the expression of thioredoxin-1 on the level of mRNA using RT-PCR and Q-PCR (A) and on the level of protein using Western blotting
(B) and the ELISA method (C), as detailed in Section 2. The inset in (C) shows details of Trx-1 protein expression (in ng/mg total protein) for MM-BI
(1), Meso-2 (2) and Ist-Met-2 cells (3). In (B), Western blotting for b-Actin is shown as a protein loading control. Data shown are mean values ± S.D.
(n = 3), images are representative of three independent experiments.
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were then exposed to a-TOS and TRAIL. Trx-1 knock-down
in Met5A cells did not sensitise them to a-TOS (Fig. 4C), while
the cells were much more susceptible to TRAIL-induced apop-
tosis (Fig. 4D). On the other hand, knocking down Trx-1 in the
malignant MM-BI cells had no eﬀect on their susceptibility to
apoptosis induced by a-TOS (Fig. 4E) or TRAIL (Fig. 4F).
In this project, we studied the role of Trx-1 in apoptosis
induction in MM and non-malignant mesothelial (Met-5A)
cells exposed to the pharmacological apoptogen a-TOS and
the immunological apoptogen TRAIL, both being selective
for cancer cells [12,35]. We found, rather surprisingly, that
(i) MM cells are resistant to TRAIL while Met-5A cells are
susceptible to TRAIL apoptosis; (ii) Met-5A cells express very
high and MM cells very low levels of Trx-1 protein, while
expression of Trx-1 mRNA is comparable; (iii) MM cells are
resistant to Trx-1 over-expression; and (iv) knocking down
Trx-1 does not change susceptibility of MM cells to apoptosis
but sensitises Met-5A cells to TRAIL killing.
Kahlos et al. showed that cancer tissue from MM patients
features higher expression of the Trx-1 protein than the non-
malignant surrounding pleura [36]. This diﬀers from our data
revealing very low levels of Trx-1 and almost 50-fold higher
levels of the protein in the non-malignant Met-5A cells. At
the same time, we found comparable levels of Trx-1 mRNA
in both the malignant and non-malignant cells. It is possible
that mRNA of MM cells contains a silencer that suppresses
eﬃcient translation. Since the MM cell lines are originally ex-
planted from MM patients, they represent a valid cellular
model of MM. Moreover, the MM cell lines used in thisstudy are of the sarcomatose, epithelioid and biphasic pheno-
type, while the Met-5A cells are SV40-immortalised cells de-
rived from normal human pleura [29]. The fact that high level
of expression of the Trx-1 protein in Met-5A cells is not due
to their immortalisation with SV40 was documented by
assessing for Trx1 expression in two unrelated, non-malig-
nant cell lines, the rat left ventricular myocytes HL-1 and
the human endothelial cells EAhy926. In both cases, the lev-
els of the protein were comparable with those in Met-5A cells
(not shown).
The role of Trx-1 in cancer is unclear at present. While it has
been suggested that high levels of expression of the redox-ac-
tive protein may be positively associated with the metastatic
potential of cancers and, in general, with cancer etiology, it
is possible that high expression of Trx-1 may be anti-apoptotic
since it may act as a reductant of ROS generated by cancer
cells in response to a variety of anti-cancer/pro-apoptotic
agents [37,38]. It has been established that Trx-1 also regulates
apoptosis via a redox-independent manner, by modulating the
ASK1 protein, a constituent of the MAP kinase cascade [28].
Our data suggest that in mesothelioma, the role of Trx-1 in
regulation of apoptosis may be independent of its redox activ-
ity, since its modulation does not aﬀect susceptibility of the
cells to a-TOS. In fact, knocking down Trx1 in the TRAIL-
sensitive Met-5A cells makes them even more susceptible to
the immunological apoptogen.
In conclusion, we suggest that Trx-1 may have little role of
apoptosis in MM cells, while it may be anti-apoptotic for
non-malignant mesothelial cells exposed to TRAIL, via its re-
dox-unrelated properties.
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Fig. 4. Knocking down Trx-1 levels sensitises non-malignant mesothe-
lial cells to TRAIL apoptosis. Met5A and MM-BI cells were seeded in
24-well plates and treated with Trx-1 siRNA (Duplex 1, Duplex 2, orNS
siRNA) as detailed in Section 2, and the level of Trx-1 protein expression
assessedby theELISAmethod (A,Met5Acells; B,MM-BI cells).Met5A
cells pre-treated with Duplex 2 siRNA (C and E) and MM-BI cells pre-
treated with Duplex 1 siRNA (D and F) were exposed to 50 lM a-TOS
(C and D) or 30 ng/ml TRAIL (E and F) at concentrations and times
shown, harvested, and assessed for apoptosis using the annexin V
method. Data shown are mean values ± S.D. (n = 3).
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